NDAORALTABLET
Approved
Oct 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENESE-R is a fixed-dose oral antihypertensive combining polythiazide (a thiazide diuretic) and reserpine (an antiadrenergic agent). It was developed to treat hypertension by combining diuretic and sympatholytic mechanisms. This product represents an early fixed-dose combination approach to blood pressure management.
LOE Approaching
Product is approaching loss of exclusivity with modest competitive pressure (30), suggesting a small-to-transitional brand team focused on managed decline and legacy support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RENESE-R offers limited career growth opportunities, as the product is in managed decline with minimal linked job openings (0 identified). This role is best suited for professionals seeking experience in legacy brand management, regulatory compliance, or supply-chain optimization in a mature market.
Brand ManagerProduct Manager
Worked on RENESE-R at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.